KRAS and pancreatic neoplasm: Although, SMAD4 was not genetically co-occurred with TP53 and CDKN2A, the expression levels of SMAD4 were also relatively higher in pancreatic cancer patients with KRAS mutation, TP53 mutation or CDKN2A deletion (Figure 3E).